To some extent, the hypothesis could be supported by the enhancement of ERK or MK2 signaling pathways in cancers, such as prostate cancer and bladder cancer, which presented down-regulation of PDE4 expression34,35. Here, MAPKAPK2 is linked to urinary bladder cancer.